Ceftazidime/avibactam apparaît comme un choix antibiotique performant en cas d’infections dues à une K. pneumoniae productrice de carbapénèmase. ( I Karaiskos et al. & Hellenic Ceftazidime/Avibactam Registry Study Group )

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.

| Dr Olivier leroy

Rationnel Les K. pneumoniae producteurs de carbapénèmases sont parmi les pathogènes nosocomiaux émergents. Les antibiotiques de dernier recours usuels sont … Suite  

Treatment of Carbapenem-Resistant Enterobacterales: guidelines from IDSA. ( Pranita D. Tamma and al. )

Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections A Focus on Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

| Dr Jean-Pierre Bru

The IDSA publishes guidelines for the treatment of infections due to Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas … Suite